Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110


HER2 expression identifies dynamic functional states within circulating breast cancer cells.

Jordan NV, Bardia A, Wittner BS, Benes C, Ligorio M, Zheng Y, Yu M, Sundaresan TK, Licausi JA, Desai R, O'Keefe RM, Ebright RY, Boukhali M, Sil S, Onozato ML, Iafrate AJ, Kapur R, Sgroi D, Ting DT, Toner M, Ramaswamy S, Haas W, Maheswaran S, Haber DA.

Nature. 2016 Sep 1;537(7618):102-106. doi: 10.1038/nature19328. Epub 2016 Aug 24.


Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy.

Hainsworth JD, Murphy PB, Alemar JR, Daniel BR, Young RR, Yardley DA.

Breast Cancer Res Treat. 2016 Nov;160(1):41-49. Epub 2016 Sep 8.


Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.

Beije N, Onstenk W, Kraan J, Sieuwerts AM, Hamberg P, Dirix LY, Brouwer A, de Jongh FE, Jager A, Seynaeve CM, Van NM, Foekens JA, Martens JW, Sleijfer S.

Neoplasia. 2016 Nov;18(11):647-653. doi: 10.1016/j.neo.2016.08.007. Epub 2016 Oct 17.


Circulating tumour cells: insights into tumour heterogeneity.

Hayes DF, Paoletti C.

J Intern Med. 2013 Aug;274(2):137-43. doi: 10.1111/joim.12047. Review.


EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.

Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G.

Breast Cancer Res Treat. 2010 Aug;122(3):685-97. doi: 10.1007/s10549-009-0592-x. Epub 2009 Oct 27.


Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.

Agelaki S, Kalykaki A, Markomanolaki H, Papadaki MA, Kallergi G, Hatzidaki D, Kalbakis K, Mavroudis D, Georgoulias V.

PLoS One. 2015 Jun 17;10(6):e0123683. doi: 10.1371/journal.pone.0123683. eCollection 2015.


Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling.

Nakanishi T, Chumsri S, Khakpour N, Brodie AH, Leyland-Jones B, Hamburger AW, Ross DD, Burger AM.

Br J Cancer. 2010 Mar 2;102(5):815-26. doi: 10.1038/sj.bjc.6605553. Epub 2010 Feb 9.


ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.

Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L.

Oncogene. 2008 Aug 28;27(37):5019-32. doi: 10.1038/onc.2008.149. Epub 2008 May 12.


The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.

Gilani RA, Kazi AA, Shah P, Schech AJ, Chumsri S, Sabnis G, Jaiswal AK, Brodie AH.

Breast Cancer Res Treat. 2012 Oct;135(3):681-92. doi: 10.1007/s10549-012-2148-8. Epub 2012 Aug 10.


The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.

Wallwiener M, Hartkopf AD, Riethdorf S, Nees J, Sprick MR, Schönfisch B, Taran FA, Heil J, Sohn C, Pantel K, Trumpp A, Schneeweiss A.

BMC Cancer. 2015 May 14;15:403. doi: 10.1186/s12885-015-1423-6.


Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.

Fan P, McDaniel RE, Kim HR, Clagett D, Haddad B, Jordan VC.

Eur J Cancer. 2012 Dec;48(18):3488-98. doi: 10.1016/j.ejca.2012.04.020. Epub 2012 Jun 2.


Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.

Chen AC, Migliaccio I, Rimawi M, Lopez-Tarruella S, Creighton CJ, Massarweh S, Huang C, Wang YC, Batra SK, Gutierrez MC, Osborne CK, Schiff R.

Breast Cancer Res Treat. 2012 Jul;134(2):583-93. doi: 10.1007/s10549-012-2082-9. Epub 2012 May 29.


Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.

Somlo G, Lau SK, Frankel P, Hsieh HB, Liu X, Yang L, Krivacic R, Bruce RH.

Breast Cancer Res Treat. 2011 Jul;128(1):155-63. doi: 10.1007/s10549-011-1508-0. Epub 2011 Apr 16.


Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.

Kallergi G, Agelaki S, Papadaki MA, Nasias D, Matikas A, Mavroudis D, Georgoulias V.

Breast Cancer Res. 2015 Aug 19;17:113. doi: 10.1186/s13058-015-0624-x.


A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.

Chihara Y, Shimoda M, Hori A, Ohara A, Naoi Y, Ikeda JI, Kagara N, Tanei T, Shimomura A, Shimazu K, Kim SJ, Noguchi S.

Breast Cancer Res Treat. 2017 Nov;166(1):55-68. doi: 10.1007/s10549-017-4382-6. Epub 2017 Jul 12.


Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.

Munzone E, Botteri E, Sandri MT, Esposito A, Adamoli L, Zorzino L, Sciandivasci A, Cassatella MC, Rotmensz N, Aurilio G, Curigliano G, Goldhirsch A, Nolè F.

Clin Breast Cancer. 2012 Oct;12(5):340-6. doi: 10.1016/j.clbc.2012.07.001.


Frequency of HER2 expression of circulating tumour cells in patients with metastatic or recurrent gastrointestinal cancer.

Iwatsuki M, Toyoshima K, Watanabe M, Hayashi N, Ishimoto T, Eto K, Iwagami S, Baba Y, Yoshida N, Hayashi A, Ohta Y, Baba H.

Br J Cancer. 2013 Nov 26;109(11):2829-32. doi: 10.1038/bjc.2013.680. Epub 2013 Nov 7.


Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.

Aktas B, Kasimir-Bauer S, Müller V, Janni W, Fehm T, Wallwiener D, Pantel K, Tewes M; DETECT Study Group.

BMC Cancer. 2016 Jul 25;16:522. doi: 10.1186/s12885-016-2587-4.


Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer.

Cheng F, Zhao J, Hanker AB, Brewer MR, Arteaga CL, Zhao Z.

Breast Cancer Res Treat. 2016 Dec;160(3):457-474. doi: 10.1007/s10549-016-4011-9. Epub 2016 Oct 22.


Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.

Agelaki S, Dragolia M, Markonanolaki H, Alkahtani S, Stournaras C, Georgoulias V, Kallergi G.

Oncotarget. 2017 Jan 17;8(3):5309-5322. doi: 10.18632/oncotarget.14144.

Supplemental Content

Support Center